- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- March 2025
- 190 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 195 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- August 2024
- 100 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- March 2025
- 250 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 150 Pages
Global
From €4611EUR$4,850USD£3,873GBP
- Report
- May 2024
- 137 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- February 2025
- 183 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- September 2024
- 115 Pages
Global
From €14255EUR$14,995USD£11,976GBP
- Report
- July 2021
Global
From €902EUR$949USD£758GBP
- Report
- March 2025
Global
From €400EUR$451USD£348GBP
- Report
- October 2023
- 85 Pages
United States
From €4611EUR$4,850USD£3,873GBP
- Report
- October 2022
- 270 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Report
- April 2021
- 40 Pages
China
From €2472EUR$2,600USD£2,076GBP
- Report
- February 2024
- 30 Pages
United States
€2139EUR$2,250USD£1,797GBP
- Report
- February 2022
- 210 Pages
Global
From €7130EUR$7,500USD£5,990GBP
- Report
- January 2022
- 90 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- January 2024
- 113 Pages
Global
From €4278EUR$4,500USD£3,594GBP

Humira is a biologic drug used to treat psoriasis, a chronic skin condition. It is a monoclonal antibody that works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Humira is the most widely prescribed biologic drug for psoriasis, and is used to treat moderate to severe cases of the condition. It is administered via subcutaneous injection, and is typically used in combination with other treatments such as topical medications and phototherapy.
Humira is a part of a larger market of psoriasis drugs, which includes other biologics such as Enbrel and Remicade, as well as traditional treatments such as topical corticosteroids and vitamin D analogues. The market is highly competitive, with many companies vying for a share of the market.
Some of the companies in the psoriasis drug market include AbbVie, Amgen, Janssen, Novartis, Pfizer, and UCB. Show Less Read more